Biotechnology company Moderna Inc. (NASDAQ: MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a next-generation therapy. In a nutshell, mRNA therapy involves using messenger RNA molecules to deliver instructions to cells to produce certain proteins that can trigger an immune response or target disease-causing proteins like cancer. mRNA therapy has the potential to treat infectious diseases like RSV, Zika, and HIV, as well as help create cancer vaccines. However, the company has struggled to diversify revenues as COVID-19 therapies still generate the majority of its revenues, which have been on a downward trajectory for years.
